Fluvoxamine
Fluvoxamine

Fluvoxamine Comprehensive Study by Application (Obsessive-Compulsive Disorder, Social Phobia, Panic Disorder, Posttraumatic Stress Disorder), Side Effect (Nausea, Sleepiness, Weakness, Dizziness, Other), Dosage Forms (25mg, 50mg, 100mg) Players and Region - Global Market Outlook to 2027

Fluvoxamine Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

May 2022 Edition 213 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Fluvoxamine Market?

Fluvoxamine is a selective serotonin reuptake inhibitor that has been approved by the Food and Drug Administration (FDA) for the therapies of intense disorder and is also used to treat other conditions such as depression. Fluvoxamine is not approved by the Food and Drugs To treat any infestation. Fluvoxamine is prescribed to patients suffering from obsessive-compulsive disorder (OCD). It assists in reducing unwanted or persistent thoughts (obsessions), as well as the urge to perform repetitive tasks (compulsions such as hand-washing, counting, and checking) that interfere with daily living. Fluvoxamine is a serotonin reuptake inhibitor that works selectively (SSRI). This medication works by restoring the balance of a natural substance in the brain called serotonin.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledTeva Pharmaceuticals (Israel), Abbott (United States), Pfizer (United States), Eli Lilly (United States), Livzon (China), Takeda (Japan), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India) and Novartis AG (Switzerland
CAGR%


The market study is being classified, by Application (Obsessive-Compulsive Disorder, Social Phobia, Panic Disorder and Posttraumatic Stress Disorder) and major geographies with country level break-up.

Teva Pharmaceuticals (Israel), Abbott (United States), Pfizer (United States), Eli Lilly (United States), Livzon (China), Takeda (Japan), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India) and Novartis AG (Switzerland are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Merck KGaA (Germany) and Apotex Inc. (Canada).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Fluvoxamine market throughout the forecasted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Fluvoxamine market by Type, Application and Region.

On the basis of geography, the market of Fluvoxamine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Rising Prevalence Rate Of Chronic Conditions
  • Development In The Healthcare Industry

Market Trend
  • Advanced Technology Developments To Discover New High Potential Drugs Create An Opportunity

Restraints
  • Allergic Reactions And Side Effects Due To Some Fluvoxamine Drugs

Opportunities
  • The Rise In The Investment In Research And Development By Public And Private Organizations
  • Increasing Pediatric Population Across The Globe

Challenges
  • Consumerís Preference Towards Herbal Medicines


Market Leaders and some development strategies
On 19 April 2022, Roche Pharmaceuticals China announced on that it has entered into an innovative collaboration agreement with Teva Pharmaceuticals, a leading Israeli pharmaceutical company, to combine respective strengths and resources to further expand the availability of the original drug Treanda in China.



Key Target Audience
New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Fluvoxamine Market?
"The Rising Prevalence Rate Of Chronic Conditions " is seen as one of major growth factors of Fluvoxamine Market in years to come.

2. Can we have customized study for Fluvoxamine Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Fluvoxamine Market?
United States will lead Fluvoxamine Market in coming years.
Report Objectives / Segmentation Covered
By Application
  • Obsessive-Compulsive Disorder
  • Social Phobia
  • Panic Disorder
  • Posttraumatic Stress Disorder
By Side Effect
  • Nausea
  • Sleepiness
  • Weakness
  • Dizziness
  • Other

By Dosage Forms
  • 25mg
  • 50mg
  • 100mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Prevalence Rate Of Chronic Conditions
      • 3.2.2. Development In The Healthcare Industry
    • 3.3. Market Challenges
      • 3.3.1. Consumerís Preference Towards Herbal Medicines
    • 3.4. Market Trends
      • 3.4.1. Advanced Technology Developments To Discover New High Potential Drugs Create An Opportunity
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fluvoxamine, by Application, Side Effect , Dosage Forms and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Fluvoxamine (Value)
      • 5.2.1. Global Fluvoxamine by: Application (Value)
        • 5.2.1.1. Obsessive-Compulsive Disorder
        • 5.2.1.2. Social Phobia
        • 5.2.1.3. Panic Disorder
        • 5.2.1.4. Posttraumatic Stress Disorder
      • 5.2.2. Global Fluvoxamine by: Dosage Forms (Value)
        • 5.2.2.1. 25mg
        • 5.2.2.2. 50mg
        • 5.2.2.3. 100mg
      • 5.2.3. Global Fluvoxamine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Fluvoxamine (Price)
  • 6. Fluvoxamine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceuticals (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Livzon (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Fluvoxamine Sale, by Application, Side Effect , Dosage Forms and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Fluvoxamine (Value)
      • 7.2.1. Global Fluvoxamine by: Application (Value)
        • 7.2.1.1. Obsessive-Compulsive Disorder
        • 7.2.1.2. Social Phobia
        • 7.2.1.3. Panic Disorder
        • 7.2.1.4. Posttraumatic Stress Disorder
      • 7.2.2. Global Fluvoxamine by: Dosage Forms (Value)
        • 7.2.2.1. 25mg
        • 7.2.2.2. 50mg
        • 7.2.2.3. 100mg
      • 7.2.3. Global Fluvoxamine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Fluvoxamine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fluvoxamine: by Application(USD Million)
  • Table 2. Fluvoxamine Obsessive-Compulsive Disorder , by Region USD Million (2016-2021)
  • Table 3. Fluvoxamine Social Phobia , by Region USD Million (2016-2021)
  • Table 4. Fluvoxamine Panic Disorder , by Region USD Million (2016-2021)
  • Table 5. Fluvoxamine Posttraumatic Stress Disorder , by Region USD Million (2016-2021)
  • Table 6. Fluvoxamine: by Dosage Forms(USD Million)
  • Table 7. Fluvoxamine 25mg , by Region USD Million (2016-2021)
  • Table 8. Fluvoxamine 50mg , by Region USD Million (2016-2021)
  • Table 9. Fluvoxamine 100mg , by Region USD Million (2016-2021)
  • Table 10. South America Fluvoxamine, by Country USD Million (2016-2021)
  • Table 11. South America Fluvoxamine, by Application USD Million (2016-2021)
  • Table 12. South America Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 13. South America Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 14. Brazil Fluvoxamine, by Application USD Million (2016-2021)
  • Table 15. Brazil Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 16. Brazil Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 17. Argentina Fluvoxamine, by Application USD Million (2016-2021)
  • Table 18. Argentina Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 19. Argentina Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 20. Rest of South America Fluvoxamine, by Application USD Million (2016-2021)
  • Table 21. Rest of South America Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 22. Rest of South America Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 23. Asia Pacific Fluvoxamine, by Country USD Million (2016-2021)
  • Table 24. Asia Pacific Fluvoxamine, by Application USD Million (2016-2021)
  • Table 25. Asia Pacific Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 26. Asia Pacific Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 27. China Fluvoxamine, by Application USD Million (2016-2021)
  • Table 28. China Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 29. China Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 30. Japan Fluvoxamine, by Application USD Million (2016-2021)
  • Table 31. Japan Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 32. Japan Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 33. India Fluvoxamine, by Application USD Million (2016-2021)
  • Table 34. India Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 35. India Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 36. South Korea Fluvoxamine, by Application USD Million (2016-2021)
  • Table 37. South Korea Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 38. South Korea Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 39. Taiwan Fluvoxamine, by Application USD Million (2016-2021)
  • Table 40. Taiwan Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 41. Taiwan Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 42. Australia Fluvoxamine, by Application USD Million (2016-2021)
  • Table 43. Australia Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 44. Australia Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Fluvoxamine, by Application USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 48. Europe Fluvoxamine, by Country USD Million (2016-2021)
  • Table 49. Europe Fluvoxamine, by Application USD Million (2016-2021)
  • Table 50. Europe Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 51. Europe Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 52. Germany Fluvoxamine, by Application USD Million (2016-2021)
  • Table 53. Germany Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 54. Germany Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 55. France Fluvoxamine, by Application USD Million (2016-2021)
  • Table 56. France Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 57. France Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 58. Italy Fluvoxamine, by Application USD Million (2016-2021)
  • Table 59. Italy Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 60. Italy Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 61. United Kingdom Fluvoxamine, by Application USD Million (2016-2021)
  • Table 62. United Kingdom Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 63. United Kingdom Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 64. Netherlands Fluvoxamine, by Application USD Million (2016-2021)
  • Table 65. Netherlands Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 66. Netherlands Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 67. Rest of Europe Fluvoxamine, by Application USD Million (2016-2021)
  • Table 68. Rest of Europe Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 69. Rest of Europe Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 70. MEA Fluvoxamine, by Country USD Million (2016-2021)
  • Table 71. MEA Fluvoxamine, by Application USD Million (2016-2021)
  • Table 72. MEA Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 73. MEA Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 74. Middle East Fluvoxamine, by Application USD Million (2016-2021)
  • Table 75. Middle East Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 76. Middle East Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 77. Africa Fluvoxamine, by Application USD Million (2016-2021)
  • Table 78. Africa Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 79. Africa Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 80. North America Fluvoxamine, by Country USD Million (2016-2021)
  • Table 81. North America Fluvoxamine, by Application USD Million (2016-2021)
  • Table 82. North America Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 83. North America Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 84. United States Fluvoxamine, by Application USD Million (2016-2021)
  • Table 85. United States Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 86. United States Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 87. Canada Fluvoxamine, by Application USD Million (2016-2021)
  • Table 88. Canada Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 89. Canada Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 90. Mexico Fluvoxamine, by Application USD Million (2016-2021)
  • Table 91. Mexico Fluvoxamine, by Side Effect USD Million (2016-2021)
  • Table 92. Mexico Fluvoxamine, by Dosage Forms USD Million (2016-2021)
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Fluvoxamine: by Application(USD Million)
  • Table 103. Fluvoxamine Obsessive-Compulsive Disorder , by Region USD Million (2022-2027)
  • Table 104. Fluvoxamine Social Phobia , by Region USD Million (2022-2027)
  • Table 105. Fluvoxamine Panic Disorder , by Region USD Million (2022-2027)
  • Table 106. Fluvoxamine Posttraumatic Stress Disorder , by Region USD Million (2022-2027)
  • Table 107. Fluvoxamine: by Dosage Forms(USD Million)
  • Table 108. Fluvoxamine 25mg , by Region USD Million (2022-2027)
  • Table 109. Fluvoxamine 50mg , by Region USD Million (2022-2027)
  • Table 110. Fluvoxamine 100mg , by Region USD Million (2022-2027)
  • Table 111. South America Fluvoxamine, by Country USD Million (2022-2027)
  • Table 112. South America Fluvoxamine, by Application USD Million (2022-2027)
  • Table 113. South America Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 114. South America Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 115. Brazil Fluvoxamine, by Application USD Million (2022-2027)
  • Table 116. Brazil Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 117. Brazil Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 118. Argentina Fluvoxamine, by Application USD Million (2022-2027)
  • Table 119. Argentina Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 120. Argentina Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 121. Rest of South America Fluvoxamine, by Application USD Million (2022-2027)
  • Table 122. Rest of South America Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 123. Rest of South America Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 124. Asia Pacific Fluvoxamine, by Country USD Million (2022-2027)
  • Table 125. Asia Pacific Fluvoxamine, by Application USD Million (2022-2027)
  • Table 126. Asia Pacific Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 127. Asia Pacific Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 128. China Fluvoxamine, by Application USD Million (2022-2027)
  • Table 129. China Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 130. China Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 131. Japan Fluvoxamine, by Application USD Million (2022-2027)
  • Table 132. Japan Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 133. Japan Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 134. India Fluvoxamine, by Application USD Million (2022-2027)
  • Table 135. India Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 136. India Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 137. South Korea Fluvoxamine, by Application USD Million (2022-2027)
  • Table 138. South Korea Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 139. South Korea Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 140. Taiwan Fluvoxamine, by Application USD Million (2022-2027)
  • Table 141. Taiwan Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 142. Taiwan Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 143. Australia Fluvoxamine, by Application USD Million (2022-2027)
  • Table 144. Australia Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 145. Australia Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 146. Rest of Asia-Pacific Fluvoxamine, by Application USD Million (2022-2027)
  • Table 147. Rest of Asia-Pacific Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 148. Rest of Asia-Pacific Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 149. Europe Fluvoxamine, by Country USD Million (2022-2027)
  • Table 150. Europe Fluvoxamine, by Application USD Million (2022-2027)
  • Table 151. Europe Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 152. Europe Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 153. Germany Fluvoxamine, by Application USD Million (2022-2027)
  • Table 154. Germany Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 155. Germany Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 156. France Fluvoxamine, by Application USD Million (2022-2027)
  • Table 157. France Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 158. France Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 159. Italy Fluvoxamine, by Application USD Million (2022-2027)
  • Table 160. Italy Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 161. Italy Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 162. United Kingdom Fluvoxamine, by Application USD Million (2022-2027)
  • Table 163. United Kingdom Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 164. United Kingdom Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 165. Netherlands Fluvoxamine, by Application USD Million (2022-2027)
  • Table 166. Netherlands Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 167. Netherlands Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 168. Rest of Europe Fluvoxamine, by Application USD Million (2022-2027)
  • Table 169. Rest of Europe Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 170. Rest of Europe Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 171. MEA Fluvoxamine, by Country USD Million (2022-2027)
  • Table 172. MEA Fluvoxamine, by Application USD Million (2022-2027)
  • Table 173. MEA Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 174. MEA Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 175. Middle East Fluvoxamine, by Application USD Million (2022-2027)
  • Table 176. Middle East Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 177. Middle East Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 178. Africa Fluvoxamine, by Application USD Million (2022-2027)
  • Table 179. Africa Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 180. Africa Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 181. North America Fluvoxamine, by Country USD Million (2022-2027)
  • Table 182. North America Fluvoxamine, by Application USD Million (2022-2027)
  • Table 183. North America Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 184. North America Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 185. United States Fluvoxamine, by Application USD Million (2022-2027)
  • Table 186. United States Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 187. United States Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 188. Canada Fluvoxamine, by Application USD Million (2022-2027)
  • Table 189. Canada Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 190. Canada Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 191. Mexico Fluvoxamine, by Application USD Million (2022-2027)
  • Table 192. Mexico Fluvoxamine, by Side Effect USD Million (2022-2027)
  • Table 193. Mexico Fluvoxamine, by Dosage Forms USD Million (2022-2027)
  • Table 194. Research Programs/Design for This Report
  • Table 195. Key Data Information from Secondary Sources
  • Table 196. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fluvoxamine: by Application USD Million (2016-2021)
  • Figure 5. Global Fluvoxamine: by Dosage Forms USD Million (2016-2021)
  • Figure 6. South America Fluvoxamine Share (%), by Country
  • Figure 7. Asia Pacific Fluvoxamine Share (%), by Country
  • Figure 8. Europe Fluvoxamine Share (%), by Country
  • Figure 9. MEA Fluvoxamine Share (%), by Country
  • Figure 10. North America Fluvoxamine Share (%), by Country
  • Figure 11. Global Fluvoxamine share by Players 2021 (%)
  • Figure 12. Global Fluvoxamine share by Players (Top 3) 2021(%)
  • Figure 13. Global Fluvoxamine share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 16. Teva Pharmaceuticals (Israel) Revenue: by Geography 2021
  • Figure 17. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott (United States) Revenue: by Geography 2021
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2021
  • Figure 21. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 23. Livzon (China) Revenue, Net Income and Gross profit
  • Figure 24. Livzon (China) Revenue: by Geography 2021
  • Figure 25. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Takeda (Japan) Revenue: by Geography 2021
  • Figure 27. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) Revenue: by Geography 2021
  • Figure 29. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2021
  • Figure 31. Novartis AG (Switzerland Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland Revenue: by Geography 2021
  • Figure 33. Global Fluvoxamine: by Application USD Million (2022-2027)
  • Figure 34. Global Fluvoxamine: by Dosage Forms USD Million (2022-2027)
  • Figure 35. South America Fluvoxamine Share (%), by Country
  • Figure 36. Asia Pacific Fluvoxamine Share (%), by Country
  • Figure 37. Europe Fluvoxamine Share (%), by Country
  • Figure 38. MEA Fluvoxamine Share (%), by Country
  • Figure 39. North America Fluvoxamine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceuticals (Israel)
  • Abbott (United States)
  • Pfizer (United States)
  • Eli Lilly (United States)
  • Livzon (China)
  • Takeda (Japan)
  • Sanofi (France)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Novartis AG (Switzerland
Additional players considered in the study are as follows:
Merck KGaA (Germany) , Apotex Inc. (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation